Product candidates for the treatment of vaginal yeast infections, Alzheimer’s disease, cystic fibrosis in children, low blood pressure, severe thermal burns and more face PDUFA dates – the deadlines by which the FDA must review new drug applications – this month. As PDUFA dates can serve as catalysts for stocks, biotech investors can be well served by paying attention to them. For the key FDA approvals scheduled for the coming weeks, CLICK HERE.
Key PDUFA Dates – And Biotech Stock Catalysts – In June
- by Alex Clarke
